Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo
Top Cited Papers
- 1 December 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (48), 20270-20275
- https://doi.org/10.1073/pnas.0909411106
Abstract
Δ9-Tetrahydrocannabinol (THC), the psychoactive component of marijuana, and other direct cannabinoid receptor (CB1) agonists produce a number of neurobehavioral effects in mammals that range from the beneficial (analgesia) to the untoward (abuse potential). Why, however, this full spectrum of activities is not observed upon pharmacological inhibition or genetic deletion of either fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), enzymes that regulate the two major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively, has remained unclear. Here, we describe a selective and efficacious dual FAAH/MAGL inhibitor, JZL195, and show that this agent exhibits broad activity in the tetrad test for CB1 agonism, causing analgesia, hypomotilty, and catalepsy. Comparison of JZL195 to specific FAAH and MAGL inhibitors identified behavioral processes that were regulated by a single endocannabinoid pathway (e.g., hypomotility by the 2-AG/MAGL pathway) and, interestingly, those where disruption of both FAAH and MAGL produced additive effects that were reversed by a CB1 antagonist. Falling into this latter category was drug discrimination behavior, where dual FAAH/MAGL blockade, but not disruption of either FAAH or MAGL alone, produced THC-like responses that were reversed by a CB1 antagonist. These data indicate that AEA and 2-AG signaling pathways interact to regulate specific behavioral processes in vivo, including those relevant to drug abuse, thus providing a potential mechanistic basis for the distinct pharmacological profiles of direct CB1 agonists and inhibitors of individual endocannabinoid degradative enzymes.Keywords
This publication has 45 references indexed in Scilit:
- Characterization of Monoacylglycerol Lipase Inhibition Reveals Differences in Central and Peripheral Endocannabinoid MetabolismCell Chemical Biology, 2009
- Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic PainThe Journal of pharmacology and experimental therapeutics, 2009
- Inhibitors of Endocannabinoid-Metabolizing Enzymes Reduce Precipitated Withdrawal Responses in THC-Dependent MiceThe AAPS Journal, 2009
- Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory PainCell Chemical Biology, 2009
- Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effectsNature Chemical Biology, 2008
- Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levelsBioorganic & Medicinal Chemistry Letters, 2008
- The Endogenous Cannabinoid System Modulates Nicotine Reward and DependenceThe Journal of pharmacology and experimental therapeutics, 2008
- Activation of the endocannabinoid system by organophosphorus nerve agentsNature Chemical Biology, 2008
- Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous SystemChemical Reviews, 2008
- A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-ArachidonoylglycerolCell Chemical Biology, 2007